PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
Saved in:
| Title: | PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition. |
|---|---|
| Authors: | McNeill RS; Pathobiology and Translational Science Graduate Program, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Stroobant EE; Department of Chemistry, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Smithberger E; Pathobiology and Translational Science Graduate Program, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Canoutas DA; Department of Biology, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Butler MK; Department of Biology, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Shelton AK; Pathobiology and Translational Science Graduate Program, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Patel SD; Department of Chemistry, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Limas JC; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Skinner KR; Neurosciences Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Bash RE; Departments of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Schmid RS; Neurosciences Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America., Miller CR; Pathobiology and Translational Science Graduate Program, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.; Neurosciences Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.; Departments of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America.; Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, NC, United States of America. |
| Source: | PloS one [PLoS One] 2018 Jul 05; Vol. 13 (7), pp. e0200014. Date of Electronic Publication: 2018 Jul 05 (Print Publication: 2018). |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0200014 |
